Esperoct® (turoctocog alfa pegol, N8-GP) approved in the EU ... Read more


Novo Nordisk's operating profit increased by 14% in Danish kroner and by 8% at c ... Read more


Esperoct® (turoctocog alfa pegol, N8-GP) approved in the EU ... Read more


Novo Nordisk A/S - Share repurchase programme ... Read more


Novo Nordisk A/S - Share repurchase programme ... Read more


Novo Nordisk A/S - Share repurchase programme ... Read more

Contact Media

If you have any queries please feel free to contact Media Relations at Novo Nordisk headquarters or one of our global offices.

Contact Media Relations
Press material is intended for media.


Novo Nordisk Media

production Denmark

Novo Nordisk's operating profit increased by 14% in Danish kroner and by 8% at constant exchange rates (CER) in the first three months of 2019

Lars Fruergaard Jørgensen, president and CEO: "We delivered very solid performance in International Operations, driven by sales growth in all regions; meanwhile, sales in the USA were negatively impacted by inventory reductions. The global launch of Ozempic®, our new once-weekly GLP-1, is well on track and continues to gain market share. From a regulatory perspective, we achieved important milestones with the filing of oral semaglutide both in the USA and the EU. Based on the progress we made in the first quarter of 2019, we are on track to deliver on our outlook for the full-year.”

Read the full announcement on Novo Nordisk's financial results for the first quarter of 2019


Circular for zero

Novo Nordisk to achieve target of 100% renewable power in production and launches new ambition aiming for zero environmental impact  

30 April - Novo Nordisk today announced that it will achieve its target to use only renewable electricity in its global production facilities by 2020. The announcement follows a new investment in a 672-acre solar panel installation, roughly the size of 500 football fields, in North Carolina, US, which will provide power to Novo Nordisk’s entire US operations from early 2020. Novo Nordisk is the first pharmaceutical company in RE100 to use only renewable electricity in production. RE100 is a collaborative, global initiative of businesses committed to using 100% renewable electricity.

Read more about Circular for Zero and download the full press release 


Novo Nordisk files for EU regulatory approval of oral semaglutide for the treatment of type 2 diabetes

26 April - Novo Nordisk today announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for oral semaglutide, a glucagon-like peptide-1 (GLP-1) analogue in a tablet taken once-daily, for the treatment of adults with type 2 diabetes.

“We are excited about the regulatory filing of oral semaglutide in Europe, the first GLP-1 receptor agonist in a tablet, as we believe oral semaglutide has the potential to further improve the treatment of adults living with type 2 diabetes.”

Oral semaglutide has now been submitted for regulatory approval in the US, the EU and Canada.  

Read the full announcement


Novo Nordisk receives positive opinion from the European regulatory authorities for Esperoct®

26 April - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), adopted a positive opinion for the use of Esperoct® (turoctocog alfa pegol, N8-GP) recommending marketing authorisation for the treatment of adolescents and adults with haemophilia A.

“We are confident that Esperoct® can provide a less burdensome and simple dosing regimen for prophylaxis and treatment of bleeding episodes, resulting in improved quality of life for people with haemophilia A.” 

Read the full announcement


Towards a cure

When Becky Furuta was told her cycling career was over due to her diabetes, she defied doctors' orders to rise to the top of her profession.

Read the story about Beckypro-cyclist at Team Novo Nordisk, or listen to her story in the podcast

Subscribe to our perspectives 


Red Cross and Novo Nordisk in ground-breaking partnership to tackle chronic care in humanitarian crises

The International Committee of the Red Cross (ICRC), the Danish Red Cross (DRC) and Novo Nordisk have partnered to tackle the growing issue of chronic diseases that affect millions of people living in humanitarian crises around the world. Focus will be on ensuring efficient supply of low-cost human insulin in vials to Red Cross globally; support for ICRC’s and DRC’s health programmes; 2-3 projects to provide care to people with hypertension and diabetes in humanitarian crises to be conducted within three years.

Read CEO Lars Fruergaard's reflections and more about the partnership



Financial results for second quarter of 2019

When Pâris was diagnosed with type 1 diabetes at the age of two, his mother Wendy began filming. She didn’t stop for 16 years. 

Watch the documentary, 'Safely in the Rainbow', on YouTube

Financial results 2019

3 May - first quarter 

9 August - first half 

1 November - third quarter 


Novo Nordisk in brief

Defeat NCDs

Zeana Massoud Said has type 1 diabetes. Zeana lives in Tanzania

The Danish Government and Novo Nordisk have announced grants of 3 and 5 million US dollars respectively to the Defeat-NCD Partnership. The aim is to raise 100 million dollars to fund mobilisation of knowledge, tools, capacities and finances to scale-up action to defeat NCDs in low-resource countries.

Read more details in the press release